Utama › Kanser Payudara › Washington

Kajian klinikal Kanser Payudara di Washington

52 kajian untuk Kanser Payudara sedang mencari peserta di lokasi di Washington.

Bandar di Washington

Teks kajian rasmi (Bahasa Inggeris)

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

University of Washington, Fred Hutchinson Cancer Center, Seattle

Mengambil pesertaFasa 1/2

Umur 12 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT04585750

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Kadlec Clinic Hematology and Onco, Kennewick
Providence Regional Cancer System, Lacey
Valley Medical Center Research, Renton
dan 1 lagi

Mengambil pesertaFasa 3

Umur 18 hingga 100 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05827081

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

Research Site, Puyallup

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07205822

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Providence Regional Cancer System-Aberdeen, Aberdeen
PeaceHealth Saint Joseph Medical Center, Bellingham
Providence Regional Cancer System-Centralia, Centralia
dan 19 lagi

Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan

Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Northwest Medical Specialties, Puyallup
Northwest Cancer Specialists, Vancouver

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07102381

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Fred Hutchinson Cancer Center, Seattle

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06625775

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Fred Hutchinson Cancer Research Center, Seattle

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT06324357

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Northwest Medical Specialties, PLLC ( Site 0062), Tacoma

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07060807

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

Fred Hutchinson Cancer Research Center, Seattle

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07222267

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Fred Hutchinson Cancer Center ( Site 0069), Seattle
Cancer Care Northwest ( Site 0003), Spokane
Northwest Medical Specialties, PLLC ( Site 0067), Tacoma

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06966700

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Northwest Medical Specialties, Bonney Lake
Northwest Medical Specialties, Federal Way
Northwest Medical Specialties, Gig Harbor
dan 3 lagi

Mengambil pesertaFasa 3

Umur 60 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06377852

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Research Site, Tacoma

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06103864

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

Fred Hutchinson Cancer Center, Seattle

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07007559

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Swedish Medical Center, Seattle

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT06618287

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Clinical Trial Site, Olympia
Clinical Trial Site, Seattle
Clinical Trial Site, Vancouver

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07085767

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Northwest Medical Specialties, PLLC, Puyallup
Fred Hutch Cancer Center, Seattle
MultiCare Cancer Institute, Tacoma

Mengambil peserta

Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07214532

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Swedish Cancer Institute - Edmonds, Edmonds
Providence Regional Cancer Partnership, Everett
UW Medicine Valley Medical Center, Renton
dan 5 lagi

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07174336

ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions

University of Washington, Seattle

Mengambil peserta

Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06085833

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Kadlec Clinic Hematology and Oncology, Kennewick
Swedish Medical Center, Seattle

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT05894239

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Northwest Medical Specialties, PLLC, Tacoma

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT07173751

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Swedish Cancer Institute - Edmonds, Edmonds
Swedish Cancer Institute - Issaquah, Issaquah
Fred Hutch CC at Evergreen HMC, Kirkland
dan 9 lagi

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT06492616

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

Fred Hutchinson Cancer Research Center, Seattle

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT06756932

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Fred Hutchinson Cancer Center, Seattle

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT06253871

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Cancer Care Northwest, Spokane Valley

Mengambil pesertaKajian pemerhatian

Umur 18 hingga 99 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT07211178

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Swedish Cancer Institute - Edmonds Campus, Edmonds
Providence Regional Cancer Partnership, Everett
Swedish Cancer Institute - Issaquah, Seattle
dan 2 lagi

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06790693

The Vanguard Study: Testing a New Way to Screen for Cancer

Madigan Army Medical Center, Tacoma

Mengambil pesertaSukarelawan sihat dialu-alukan

Umur 45 hingga 75 · Semua jantina · Dikemas kini 2 Sep 2026 · NCT06995898

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Providence Regional Cancer System-Aberdeen, Aberdeen
FHCC Overlake, Bellevue
PeaceHealth Saint Joseph Medical Center, Bellingham
dan 24 lagi

Mengambil pesertaFasa 3

Umur 18 hingga 60 · Wanita · Dikemas kini 2 Sep 2026 · NCT05879926

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Cancer Care Northwest-1 (601 S. Sherman), Spokane
Cancer Care Northwest_2 (605 E. Holland), Spokane
Cancer Care Northwest, Spokane Valley

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT06072612

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

Fred Hutch Cancer Research, Seattle

Mengambil pesertaFasa 1/2

Umur 18 hingga 100 · Semua jantina · Dikemas kini 27 Ogo 2026 · NCT06726148

Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer

Fred Hutch/University of Washington Cancer Consortium, Seattle

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 14 Ogo 2026 · NCT06518057

Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery

Swedish Cancer Institute, Seattle

Mengambil peserta

Umur 18 ke atas · Semua jantina · Dikemas kini 7 Ogo 2026 · NCT07140172

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Swedish Cancer Institute, Seattle

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 4 Ogo 2026 · NCT05579366

E-Mindfulness Approaches for Living After Breast Cancer

Saint Joseph Medical Center Hematology and Oncology - Silverdale, Silverdale

Mengambil pesertaFasa 3

Umur 18 hingga 50 · Semua jantina · Dikemas kini 4 Ogo 2026 · NCT06748222

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

University Of Washington, Seattle

Mengambil pesertaFasa 1

Umur 18 hingga 100 · Semua jantina · Dikemas kini 29 Jul 2026 · NCT06562192

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

University of Washington School of Medicine, Seattle

Mengambil pesertaFasa 2

Umur 8 ke atas · Semua jantina · Dikemas kini 27 Jul 2026 · NCT05503797

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

Fred Hutchinson Cancer Center, Seattle
Summit Cancer Centers, Spokane

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jun 2026 · NCT05377996

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Fred Hutchinson Cancer Center, Seattle

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 23 Jun 2026 · NCT06993844

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

Fred Hutch/University of Washington Cancer Consortium, Seattle

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 19 Mei 2026 · NCT06502691

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Fred Hutchinson Cancer Center, Seattle

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 18 Mei 2026 · NCT06757634

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Fred Hutchinson Cancer Center, Seattle

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 6 Mei 2026 · NCT07062965

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.